Control Bionics Ltd
ASX:CBL
Control Bionics Ltd
Research & Development
Control Bionics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Control Bionics Ltd
ASX:CBL
|
Research & Development
-AU$1.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Research & Development
-AU$443.9k
|
CAGR 3-Years
6%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-36%
|
|
|
Cochlear Ltd
ASX:COH
|
Research & Development
-AU$299.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-8%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Research & Development
-AU$4m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
Control Bionics Ltd
Glance View
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.
See Also
What is Control Bionics Ltd's Research & Development?
Research & Development
-1.1m
AUD
Based on the financial report for Jun 30, 2025, Control Bionics Ltd's Research & Development amounts to -1.1m AUD.
What is Control Bionics Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-73%
Over the last year, the Research & Development growth was 38%. The average annual Research & Development growth rates for Control Bionics Ltd have been -48% over the past three years , -73% over the past five years .
